Compare WLYB & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WLYB | HTFL |
|---|---|---|
| Founded | 1807 | 2007 |
| Country | United States | United States |
| Employees | 4500 | 843 |
| Industry | Books | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | N/A | N/A |
| Metric | WLYB | HTFL |
|---|---|---|
| Price | $54.28 | $27.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $38.20 |
| AVG Volume (30 Days) | 208.0 | ★ 1.1M |
| Earning Date | 06-16-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.04 | $27.66 |
| Revenue Next Year | $2.36 | $23.55 |
| P/E Ratio | $15.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.16 | $20.13 |
| 52 Week High | $54.73 | $41.22 |
| Indicator | WLYB | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 68.93 | 50.42 |
| Support Level | $36.32 | $25.56 |
| Resistance Level | N/A | $32.69 |
| Average True Range (ATR) | 0.23 | 1.32 |
| MACD | 0.03 | 0.42 |
| Stochastic Oscillator | 78.75 | 84.54 |
John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning, which includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.